Skip to content

Effect of STOX1 on recurrent spontaneous abortion by regulating trophoblast cell proliferation and migration via PI3K/AKT signaling pathway

Effect of STOX1 on recurrent spontaneous abortion by inhibiting trophoblast cell proliferation and migration via PI3K/AKT signaling

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019442
Enrollment
Unknown
Registered
2018-11-11
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent spontaneous abortion RSA

Interventions

Contral:0
RSA:0

Sponsors

Affiliated Anqing Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: All pregnant women presented with first-trimester inevitable miscarriage with a history of RM, defined as two or more spontaneous consecutive first-trimester miscarriages before 12 weeks gestation, were included in the study (RM group). They were clinically examined and their investigations were reviewed for different known causes of RM including antiphospholipid syndrome, and endocrinal or uterine anatomical disorders. Informed written consent was obtained for participation after reading the patient information sheet.We included in our study; pregnant women between 20 and 35 years of age with a regular marital life with the same partner and regularly menstruating before current pregnancy. Women with polycystic ovarian syndrome, any endocrinal abnormalities such as DM, thyroid disorders or history of abnormal uterine cavity proved by sonohysterography or hysteroscopy before pregnancy were excluded from the study. Also women with positive consanguinity and those who refused to participate in the study were excluded. Age-matched healthy women who had at least one normal pregnancy with no history of miscarriage had approached to participate in the study as a Control group at the time of delivery.

Exclusion criteria

Exclusion criteria: Women with polycystic ovarian syndrome, any endocrinal abnormalities such as DM, thyroid disorders or history of abnormal uterine cavity proved by sonohysterography or hysteroscopy before pregnancy were excluded from the study.

Design outcomes

Primary

MeasureTime frame
STOX1;

Countries

China

Contacts

Public ContactLI Zhi-fang

Affiliated Anqing Hospital of Anhui Medical University

184006517@qq.com+86 055 65336991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026